5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advances in liver US, CT, and MRI: moving toward the future

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the past two decades, the epidemiology of chronic liver disease has changed with an increase in the prevalence of nonalcoholic fatty liver disease in parallel to the advent of curative treatments for hepatitis C. Recent developments provided new tools for diagnosis and monitoring of liver diseases based on ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), as applied for assessing steatosis, fibrosis, and focal lesions. This narrative review aims to discuss the emerging approaches for qualitative and quantitative liver imaging, focusing on those expected to become adopted in clinical practice in the next 5 to 10 years. While radiomics is an emerging tool for many of these applications, dedicated techniques have been investigated for US (controlled attenuation parameter, backscatter coefficient, elastography methods such as point shear wave elastography [pSWE] and transient elastography [TE], novel Doppler techniques, and three-dimensional contrast-enhanced ultrasound [3D-CEUS]), CT (dual-energy, spectral photon counting, extracellular volume fraction, perfusion, and surface nodularity), and MRI (proton density fat fraction [PDFF], elastography [MRE], contrast enhancement index, relative enhancement, T1 mapping on the hepatobiliary phase, perfusion). Concurrently, the advent of abbreviated MRI protocols will help fulfill an increasing number of examination requests in an era of healthcare resource constraints.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: not found
          • Article: not found

          The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

            Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

              NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers.
                Bookmark

                Author and article information

                Contributors
                federicavernuccio@gmail.com , https://orcid.org/;
                Journal
                Eur Radiol Exp
                Eur Radiol Exp
                European Radiology Experimental
                Springer International Publishing (Cham )
                2509-9280
                7 December 2021
                7 December 2021
                December 2021
                : 5
                : 52
                Affiliations
                [1 ]Section of Radiology— Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University Hospital “Paolo Giaccone”, Via del Vespro 129, 90127 Palermo, Italy
                [2 ]GRID grid.412510.3, ISNI 0000 0004 1756 3088, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), , University Hospital of Palermo, ; Via del Vespro 129, 90127 Palermo, Italy
                [3 ]GRID grid.411599.1, ISNI 0000 0000 8595 4540, Service de radiologie, Hôpital Beaujon, , APHP.Nord, ; Clichy, France
                [4 ]Department of Radiology, Fondazione Istituto Giuseppe Giglio Ct.da Pietrapollastra, Via Pisciotto, 90015 Cefalù (Palermo), Italy
                [5 ]GRID grid.410559.c, ISNI 0000 0001 0743 2111, Department of Radiology, , Centre Hospitalier de l’Université de Montréal (CHUM), ; Montréal, Quebec Canada
                [6 ]GRID grid.410559.c, ISNI 0000 0001 0743 2111, Centre de Recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), ; Montréal, Quebec Canada
                [7 ]GRID grid.14848.31, ISNI 0000 0001 2292 3357, Department of Radiology, Radiation Oncology and Nuclear Medicine, , Université de Montréal, ; Montréal, Canada
                Author information
                http://orcid.org/0000-0003-0350-1794
                Article
                250
                10.1186/s41747-021-00250-0
                8648935
                34873633
                5b7b846b-8812-46cf-b6fe-781b60fe4dba
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 June 2021
                : 18 October 2021
                Categories
                Narrative Review
                Custom metadata
                © The Author(s) 2021

                biomarkers,non-alcoholic fatty liver disease,ultrasonography,tomography,x-ray computed,magnetic resonance imaging

                Comments

                Comment on this article